Cynthia E Dunbar

List of Publications by Year
in descending order

245 papers	16,268 citations	19657 61 h-index	18130 120 g-index
251 all docs	251 docs citations	251 times ranked	14838 citing authors

#	Article	IF	Citations
1	Prediction and validation of hematopoietic stem and progenitor cell off-target editing in transplanted rhesus macaques. Molecular Therapy, 2022, 30, 209-222.	8.2	17
2	Studies of a mosaic patient with DBA and chimeric mice reveal erythroid cellâ€“extrinsic contributions to erythropoiesis. Blood, 2022, 139, 3439-3449.	1.4	7
3	Longâ€term eltrombopag for bone marrow failure depletes iron. American Journal of Hematology, 2022, 97, 791-801.	4.1	8
4	Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans. Frontiers in Aging, 2022, 3, .	2.6	3
5	The Perfect Storm: The Workforce Crunch and the Academic Laboratory. , 2022, 19, .		7
6	A macaque clonal hematopoiesis model demonstrates expansion of TET2-disrupted clones and utility forÂtesting interventions. Blood, 2022, 140, 1774-1789.	1.4	13
7	Clonal hematopoiesis is not significantly associated with COVID-19 disease severity. Blood, 2022, 140, 1650-1655.	1.4	10
8	Clonal tracking of haematopoietic cells: insights and clinical implications. British Journal of Haematology, 2021, 192, 819-831.	2.5	10
9	A plethora of gene therapies for hemoglobinopathies. Nature Medicine, 2021, 27, 202-204.	30.7	4
10	Comparative engraftment and clonality of macaque HSPCs expanded on human umbilical vein endothelial cells versus non-expanded cells. Molecular Therapy - Methods and Clinical Development, 2021, 20, 703-715.	4.1	1
11	Interrogation of clonal tracking data using barcodetrackR. Nature Computational Science, 2021, 1, 280-289.	8.0	13
12	Understanding and overcoming adverse consequences of genome editing on hematopoietic stem and progenitor cells. Molecular Therapy, 2021, 29, 3205-3218.	8.2	14
13	Tissue Trafficking Kinetics of Rhesus Macaque Natural Killer Cells Measured by Serial Intravascular Staining. Frontiers in Immunology, 2021, 12, 772332.	4.8	2
14	CRISPR/Cas9-mediated introduction of the sodium/iodide symporter gene enables noninvasive inâ€‰vivo tracking of induced pluripotent stem cell-derived cardiomyocytes. Stem Cells Translational Medicine, 2020, 9, 1203-1217.	3.3	10
15	NADPH oxidase correction by mRNA transfection of apheresis granulocytes in chronic granulomatous disease. Blood Advances, 2020, 4, 5976-5987.	5.2	4
16	Immunosuppression and growth factors for severe aplastic anemia: new data for old questions. Haematologica, 2020, 105, 1170-1171.	3.5	4
17	<i>In Vivo</i>Tracking of Adoptively Transferred Natural Killer Cells in Rhesus Macaques Using 89Zirconium-Oxine Cell Labeling and PET Imaging. Clinical Cancer Research, 2020, 26, 2573-2581.	7.0	48
18	Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias. Blood Advances, 2020, 4, 1700-1710.	5.2	33

#	ARTICLE	IF	CITATIONS
19	Macaque CRISPR/Cas9 Age-Related Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Mutated Clones and Applicability for Testing Mitigation Approaches. Blood, 2020, 136, 27-28.	1.4	2
20	Intrabone transplantation of CD34+ cells with optimized delivery does not enhance engraftment in a rhesus macaque model. Blood Advances, 2020, 4, 6148-6156.	5.2	5
21	Clonal tracking of erythropoiesis in rhesus macaques. Haematologica, 2020, 105, 1813-1824.	3.5	5
22	A Diamond-Blackfan Anemia Patient's Response to Eltrombopag and Genomic Analysis in Different Lineages. Blood, 2020, 136, 16-17.	1.4	1
23	Long-Term Eltrombopag for Bone Marrow Failure Depletes Total Body Iron. Blood, 2020, 136, 39-40.	1.4	0
24	Busulfan Combined with Immunosuppression Allows Efficient Engraftment of Gene-Modified Cells in a Rhesus Macaque Model. Molecular Therapy, 2019, 27, 1586-1596.	8.2	28
25	Telomere dynamics and hematopoietic differentiation of human DKC1-mutant induced pluripotent stem cells. Stem Cell Research, 2019, 40, 101540.	0.7	16
26	CRISPR/Cas9 PIG-A gene editing in nonhuman primate model demonstrates no intrinsic clonal expansion of PNH HSPCs. Blood, 2019, 133, 2542-2545.	1.4	17
27	Aberrant Clonal Hematopoiesis following Lentiviral Vector Transduction of HSPCs in a Rhesus Macaque. Molecular Therapy, 2019, 27, 1074-1086.	8.2	34
28	Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag. Blood, 2019, 133, 2575-2585.	1.4	77
29	Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-Î³. Blood, 2019, 133, 2043-2055.	1.4	76
30	Impact of CMV Infection on Natural Killer Cell Clonal Repertoire in CMV-NaÃ¯ve Rhesus Macaques. Frontiers in Immunology, 2019, 10, 2381.	4.8	16
31	An All Antibody Approach for Conditioning Bone Marrow for Hematopoietic Stem Cell Transplantation with Anti-cKIT and Anti-CD47 in Non-Human Primates. Blood, 2019, 134, 4428-4428.	1.4	4
32	Efficient differentiation of cardiomyocytes and generation of calcium-sensor reporter lines from nonhuman primate iPSCs. Scientific Reports, 2018, 8, 5907.	3.3	21
33	Eltrombopag mobilizes iron in patients with aplastic anemia. Blood, 2018, 131, 2399-2402.	1.4	30
34	Gene therapy comes of age. Science, 2018, 359, .	12.6	936
35	The impact of aging on primate hematopoiesis as interrogated by clonal tracking. Blood, 2018, 131, 1195-1205.	1.4	39
36	Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemia. Experimental Hematology, 2018, 58, 39-43.	0.4	12

#	Article	IF	Citations
37	Geographic clonal tracking in macaques provides insights into HSPC migration and differentiation. Journal of Experimental Medicine, 2018, 215, 217-232.	8.5	32
38	Barcoding of Macaque Hematopoietic Stem and Progenitor Cells: A Robust Platform to Assess Vector Genotoxicity. Molecular Therapy - Methods and Clinical Development, 2018, 11, 143-154.	4.1	9
39	Clonal expansion and compartmentalized maintenance of rhesus macaque NK cell subsets. Science Immunology, 2018, 3, .	11.9	41
40	GATA2 deficiency and human hematopoietic development modeled using induced pluripotent stem cells. Blood Advances, 2018, 2, 3553-3565.	5.2	25
41	Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell, 2018, 173, 1439-1453.e19.	28.9	323
42	Genotoxic Lemons Become Epigenomic Lemonade. Cell Stem Cell, 2018, 23, 9-10.	11.1	16
43	Bone Marrow as a Source of Cells for Paroxysmal Nocturnal Hemoglobinuria Detection. American Journal of Clinical Pathology, 2018, 150, 273-282.	0.7	3
44	Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes. Blood, 2018, 132, 501-509.	1.4	52
45	An Introduction to the Analysis of Single-Cell RNA-Sequencing Data. Molecular Therapy - Methods and Clinical Development, 2018, 10, 189-196.	4.1	95
46	George Stamatoyannopoulos (1934â€“2018). Molecular Therapy, 2018, 26, 1871-1872.	8.2	1
47	Modeling Human Paroxysmal Nocturnal Hemoglobinuria Via CRISPR/Cas9 HSPC Gene Editing in Non-Human Primate. Blood, 2018, 132, 1309-1309.	1.4	0
48	Adaptive NK cells can persist in patients with GATA2 mutation depleted of stem and progenitor cells. Blood, 2017, 129, 1927-1939.	1.4	89
49	iPSCs and fibroblast subclones from the same fibroblast population contain comparable levels of sequence variations. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1964-1969.	7.1	61
50	Quantitative stability of hematopoietic stem and progenitor cell clonal output in rhesus macaques receiving transplants. Blood, 2017, 129, 1448-1457.	1.4	53
51	Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. New England Journal of Medicine, 2017, 376, 1540-1550.	27.0	393
52	Two Decades of ASGCT: Dreams Become Reality. Molecular Therapy, 2017, 25, 1057-1058.	8.2	0
53	Transcriptome analysis reveals similarities between human blood CD3â˜’ CD56bright cells and mouse CD127+ innate lymphoid cells. Scientific Reports, 2017, 7, 3501.	3.3	36
54	Rhesus Macaque iPSC Generation and Maintenance. Current Protocols in Stem Cell Biology, 2017, 41, 4A.11.1-4A.11.13.	3.0	5

#	Article	IF	Citations
55	Rhesus iPSC Safe Harbor Gene-Editing Platform for Stable Expression of Transgenes in Differentiated Cells of All Germ Layers. Molecular Therapy, 2017, 25, 44-53.	8.2	26
56	Acquired somatic mutations in PNH reveal long-term maintenance of adaptive NK cells independent of HSPCs. Blood, 2017, 129, 1940-1946.	1.4	42
57	CRISPR/Cas9â€Based Safeâ€Harbor Gene Editing in Rhesus iPSCs. Current Protocols in Stem Cell Biology, 2017, 43, 5A.11.1-5A.11.14.	3.0	6
58	Gene and Cell Therapies in Expansion Mode: ASGCT 2016. Molecular Therapy, 2016, 24, 1333-1334.	8.2	0
59	564. The Cytotoxic Effect of RNA-Guided Endonuclease Cas9 on Human Hematopoietic Stem and Progenitor Cells (HSPCs). Molecular Therapy, 2016, 24, S225-S226.	8.2	9
60	Blood â€™s 70th anniversary: CARs on the Blood highway. Blood, 2016, 128, 1-3.	1.4	14
61	Gene Editing of Human Hematopoietic Stem and Progenitor Cells: Promise and Potential Hurdles. Human Gene Therapy, 2016, 27, 729-740.	2.7	42
62	The Role of Nonhuman Primate Animal Models in the Clinical Development of Pluripotent Stem Cell Therapies. Molecular Therapy, 2016, 24, 1165-1169.	8.2	11
63	Thrombopoietic status of patients on haemodialysis. British Journal of Haematology, 2016, 172, 954-957.	2.5	9
64	Interferon-Î³ Perturbs Key Signaling Pathways Induced By Thrombopoietin, but Not Eltrombopag, in Human Hematopoietic Stem/Progenitor Cells. Blood, 2016, 128, 3870-3870.	1.4	7
65	Stochastic Modeling of Hematopoietic Stem and Progenitor Cell Barcoding Data from Rhesus Macaques Challenges the Classic Model of Hematopoiesis. Blood, 2016, 128, 2643-2643.	1.4	0
66	Human hematopoietic stem cells from mobilized peripheral blood can be purified based on CD49f integrin expression. Blood, 2015, 126, 1631-1633.	1.4	23
67	Bone marrow skeletal stem/progenitor cell defects in dyskeratosis congenita and telomere biology disorders. Blood, 2015, 125, 793-802.	1.4	31
68	Functional Niche Competition Between Normal Hematopoietic Stem and Progenitor Cells and Myeloid Leukemia Cells. Stem Cells, 2015, 33, 3635-3642.	3.2	40
69	Modeling Human Bone Marrow Failure Syndromes Using Pluripotent Stem Cells and Genome Engineering. Molecular Therapy, 2015, 23, 1832-1842.	8.2	11
70	Regulated Apoptosis of Genetically Modified Hematopoietic Stem and Progenitor Cells Via an Inducible Caspase-9 Suicide Gene in Rhesus Macaques. Stem Cells, 2015, 33, 91-100.	3.2	28
71	Eltrombopag in Aplastic Anemia. Seminars in Hematology, 2015, 52, 31-37.	3.4	34
72	An AAVS1-Targeted Minigene Platform for Correction of iPSCs From All Five Types of Chronic Granulomatous Disease. Molecular Therapy, 2015, 23, 147-157.	8.2	63

#	Article	IF	Citations
73	Identification and Ex Vivo Expansion of a Circulating NK Cell Progenitor Population That Leads to Sustained Production of CD56+ NK Cells. Blood, 2015, 126, 850-850.	1.4	1
74	Dynamics of HSPC Repopulation in Nonhuman Primates Revealed by a Decade-Long Clonal-Tracking Study. Cell Stem Cell, 2014, 14, 473-485.	11.1	87
75	Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood, 2014, 123, 3574-3577.	1.4	118
76	<scp>IFN</scp>â€Î³ regulates survival and function of tumorâ€induced <scp>CD</scp>11b⁺<scp>G</scp>râ€1^{high} myeloid derived suppressor cells by modulating the antiâ€apoptotic molecule <scp>B</scp>cl2a1. European Journal of Immunology, 2014, 44, 2457-2467.	2.9	57
77	Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood, 2014, 123, 1818-1825.	1.4	336
78	No Impact of Lentiviral Transduction on Hematopoietic Stem/Progenitor Cell Telomere Length or Gene Expression in the Rhesus Macaque Model. Molecular Therapy, 2014, 22, 52-58.	8.2	4
79	Path to the Clinic: Assessment of iPSC-Based Cell Therapies InÂVivo in a Nonhuman Primate Model. Cell Reports, 2014, 7, 1298-1309.	6.4	84
80	Clonal Tracking of Rhesus Macaque Hematopoiesis Highlights a Distinct Lineage Origin for Natural Killer Cells. Cell Stem Cell, 2014, 14, 486-499.	11.1	149
81	In vivo Clonal Tracking of Hematopoietic Stem and Progenitor Cells Marked by Five Fluorescent Proteins using Confocal and Multiphoton Microscopy. Journal of Visualized Experiments, 2014, , e51669.	0.3	8
82	Development of an inducible caspase-9 safety switch for pluripotent stem cellâ€"based therapies. Molecular Therapy - Methods and Clinical Development, 2014, 1, 14053.	4.1	59
83	Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes. International Journal of Hematology, 2013, 98, 48-55.	1.6	30
84	Assessing the Risks of Genotoxicity in the Therapeutic Development of Induced Pluripotent Stem Cells. Molecular Therapy, 2013, 21, 272-281.	8.2	44
85	High Efficiency Restriction Enzymeâ€"Free Linear Amplification-Mediated Polymerase Chain Reaction Approach for Tracking Lentiviral Integration Sites Does Not Abrogate Retrieval Bias. Human Gene Therapy, 2013, 24, 38-47.	2.7	24
86	Hematopoietic Stem Cell Gene Therapy: Assessing the Relevance of Preclinical Models. Seminars in Hematology, 2013, 50, 101-130.	3.4	22
87	Differences in the Phenotype, Cytokine Gene Expression Profiles, and In Vivo Alloreactivity of T Cells Mobilized with Plerixafor Compared with G-CSF. Journal of Immunology, 2013, 191, 6241-6249.	0.8	31
88	Integration-specific In Vitro Evaluation of Lentivirally Transduced Rhesus CD34+ Cells Correlates With In Vivo Vector Copy Number. Molecular Therapy - Nucleic Acids, 2013, 2, e122.	5.1	20
89	Defective telomere elongation and hematopoiesis from telomerase-mutant aplastic anemia iPSCs. Journal of Clinical Investigation, 2013, 123, 1952-1963.	8.2	58
90	Thymidine Kinase Suicide Gene-mediated Ganciclovir Ablation of Autologous Gene-modified Rhesus Hematopoiesis. Molecular Therapy, 2012, 20, 1932-1943.	8.2	22

#	Article	IF	Citations
91	Pharmacological Modulation of Humoral Immunity in a Nonhuman Primate Model of AAV Gene Transfer for Hemophilia B. Molecular Therapy, 2012, 20, 1410-1416.	8.2	90
92	Hematopoietic stem cell engineering at a crossroads. Blood, 2012, 119, 1107-1116.	1.4	67
93	Dynamic clonal analysis of murine hematopoietic stem and progenitor cells marked by 5 fluorescent proteins using confocal and multiphoton microscopy. Blood, 2012, 120, e105-e116.	1.4	39
94	Bone marrow homing and engraftment of human hematopoietic stem and progenitor cells is mediated by a polarized membrane domain. Blood, 2012, 119, 1848-1855.	1.4	46
95	Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia. New England Journal of Medicine, 2012, 367, 11-19.	27.0	454
96	BCL2A1a Over-Expression in Murine Hematopoietic Stem and Progenitor Cells Decreases Apoptosis and Results in Hematopoietic Transformation. PLoS ONE, 2012, 7, e48267.	2.5	21
97	CD9 up-regulation on CD34+ cells with ingenol 3,20-dibenzoate does not improve homing in NSG mice. Blood, 2011, 117, 5774-5776.	1.4	4
98	Patients, hematologists, and time. Blood, 2011, 117, 2753-2754.	1.4	0
99	Human and rhesus macaque hematopoietic stem cells cannot be purified based only on SLAM family markers. Blood, 2011, 117, 1550-1554.	1.4	46
100	Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells. Leukemia, 2011, 25, 1286-1296.	7.2	180
101	Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity. Frontiers of Medicine, 2011, 5, 356-371.	3.4	90
102	Insertion Sites in Engrafted Cells Cluster Within a Limited Repertoire of Genomic Areas After Gammaretroviral Vector Gene Therapy. Molecular Therapy, 2011, 19, 2031-2039.	8.2	48
103	Contributions of Gene Marking to Cell and Gene Therapies. Human Gene Therapy, 2011, 22, 659-668.	2.7	18
104	Telomere Dynamics in Pluripotent Stem Cells Derived From Patients with Telomere Diseases. Blood, 2011, 118, 51-51.	1.4	0
105	Keeping up with Blood: introducing our CME program. Blood, 2010, 115, 756-756.	1.4	0
106	No Evidence for Clonal Selection Due to Lentiviral Integration Sites in Human Induced Pluripotent Stem Cells. Stem Cells, 2010, 28, 687-694.	3.2	36
107	Gene therapy activates EVI1, destabilizes chromosomes. Nature Medicine, 2010, 16, 163-165.	30.7	15
108	Repetitive Busulfan Administration After Hematopoietic Stem Cell Gene Therapy Associated with a Dominant HDAC7 Clone in a Nonhuman Primate. Human Gene Therapy, 2010, 21, 695-703.	2.7	6

#	Article	IF	Citations
109	Ex Vivo Expansion of Retrovirally Transduced Primate CD34+ Cells Results in Overrepresentation of Clones With MDS1/EVI1 Insertion Sites in the Myeloid Lineage After Transplantation. Molecular Therapy, 2010, 18, 1633-1639.	8.2	20
110	Graft-versus-Host Disease: Role of Inflammation in the Development of Chromosomal Abnormalities of Keratinocytes. Biology of Blood and Marrow Transplantation, 2010, 16, 1665-1673.	2.0	18
111	Intercellular transfer to signalling endosomes regulates an ex vivo bone marrow niche. Nature Cell Biology, 2009, 11, 303-311.	10.3	90
112	Genetically Modified CD34+ Hematopoietic Stem Cells Contribute to Turnover of Brain Perivascular Macrophages in Long-Term Repopulated Primates. American Journal of Pathology, 2009, 174, 1808-1817.	3.8	47
113	More frequent Blood transfusions. Blood, 2009, 113, 6-6.	1.4	5
114	â€œGhostbustingâ€•at Blood. Blood, 2009, 113, 502-503.	1.4	11
115	Sustained high-level polyclonal hematopoietic marking and transgene expression 4 years after autologous transplantation of rhesus macaques with SIV lentiviral vectorâ€"transduced CD34+ cells. Blood, 2009, 113, 5434-5443.	1.4	48
116	Introducing â€œe-Bloodâ€• Blood, 2009, 113, 4488-4488.	1.4	0
117	Response: More on ghostbusting. Blood, 2009, 113, 5033-5034.	1.4	1
118	In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene. Journal of Clinical Investigation, 2009, 119, 1952-63.	8.2	53
119	Human and Rhesus Macaque Hematopoietic Stem Cells Are Not Enriched in the CD150+CD48- SLAM Population.. Blood, 2009, 114, 3531-3531.	1.4	0
120	Analysis of Viral Integration Sites in Human Induced Pluripotent Stem Cells.. Blood, 2009, 114, 1485-1485.	1.4	1
121	Sorting of Transgenic Secretory Proteins in Rhesus Macaque Parotid Glands After Adenovirus-Mediated Gene Transfer. Human Gene Therapy, 2008, 19, 1401-1405.	2.7	26
122	Reduced Genotoxicity of Avian Sarcoma Leukosis Virus Vectors in Rhesus Long-term Repopulating Cells Compared to Standard Murine Retrovirus Vectors. Molecular Therapy, 2008, 16, 1617-1623.	8.2	34
123	The MDS1â€"EVI1 Gene Complex as a Retrovirus Integration Site: Impact on Behavior of Hematopoietic Cells and Implications for Gene Therapy. Molecular Therapy, 2008, 16, 439-449.	8.2	60
124	Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood, 2008, 112, 2092-2100.	1.4	111
125	HOXB4 and retroviral vectors: adding fuel to the fire. Journal of Clinical Investigation, 2008, 118, 1350-1353.	8.2	4
126	Repetitive Busulfan Administration Induces Emergence of Dominant and Expanding Hematopoietic Clones with Retroviral Vector Insertion in Rhesus Macaques. Blood, 2008, 112, 3524-3524.	1.4	0

#	Article	IF	Citations
127	Culture of Mobilized Human CD34+ Cells in Hypoxic Conditions Improves Lentiviral Transduction Efficiency in SCID-Repopulating Cells. Blood, 2008, 112, 3545-3545.	1.4	0
128	A Rhesus Macaque Model to Optimize Adoptive NK Cell Therapy. Blood, 2008, 112, 3905-3905.	1.4	0
129	siRNA-Induced Transient Silencing of PTEN Expression Enhances Human Hematopoietic Cell Engraftment in NOD/SCID/Î³cnull Mice and Increases Gene Transduction Efficiency.. Blood, 2008, 112, 2329-2329.	1.4	0
130	The Yin and Yang of Stem Cell Gene Therapy: Insights into Hematopoiesis, Leukemogenesis, and Gene Therapy Safety. Hematology American Society of Hematology Education Program, 2007, 2007, 460-465.	2.5	12
131	Transduction of Rhesus Macaque Hematopoietic Stem and Progenitor Cells with Avian Sarcoma and Leukosis Virus Vectors. Human Gene Therapy, 2007, 18, 691-700.	2.7	15
132	Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood, 2007, 110, 3552-3556.	1.4	100
133	Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. Blood, 2007, 109, 5168-5177.	1.4	101
134	Keratinocyte growth factor augments immune reconstitution after autologous hematopoietic progenitor cell transplantation in rhesus macaques.. Blood, 2007, 110, 441-449.	1.4	106
135	Hematopoietic stem-cell behavior in nonhuman primates. Blood, 2007, 110, 1806-1813.	1.4	78
136	Adeno-Associated Virus Serotype 2-Mediated Gene Transfer to The Parotid Glands of Nonhuman Primates. Human Gene Therapy, 2007, 18, 142-150.	2.7	25
137	No Evidence of Clonal Dominance in Primates up to 4 Years Following Transplantation of Multidrug Resistance 1 Retrovirally Transduced Long-Term Repopulating Cells. Stem Cells, 2007, 25, 2610-2618.	3.2	17
138	Antibody-mediated cell labeling of peripheral T cells with micron-sized iron oxide particles (MPIOs) allows single cell detection by MRI. Contrast Media and Molecular Imaging, 2007, 2, 147-153.	0.8	60
139	Factors Affecting Allogeneic Peripheral Blood Stem Cell Mobilization in a Large, Ethnically, Diverse Population.. Blood, 2007, 110, 3283-3283.	1.4	0
140	PU.1 Cooperates with SOX4 in Myeloid Cells.. Blood, 2007, 110, 2633-2633.	1.4	0
141	Genotoxicity of Retroviral Integration In Hematopoietic Cells. Molecular Therapy, 2006, 13, 1031-1049.	8.2	276
142	AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood, 2006, 107, 3772-3778.	1.4	183
143	Mobilization as a preparative regimen for hematopoietic stem cell transplantation. Blood, 2006, 107, 3764-3771.	1.4	70
144	Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque. Blood, 2006, 107, 3865-3867.	1.4	129

#	Article	IF	Citations
145	Correction of the disease phenotype in canine leukocyte adhesion deficiency using ex vivo hematopoietic stem cell gene therapy. Blood, 2006, 108, 3313-3320.	1.4	44
146	Multilineage involvement of the fusion gene in patients with <i>FIP1L1/PDGFRA</i>â€positive hypereosinophilic syndrome. British Journal of Haematology, 2006, 132, 286-292.	2.5	76
147	Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nature Medicine, 2006, 12, 401-409.	30.7	1,129
148	In Vitro Culture During Retroviral Transduction Improves Thymic Repopulation and Output After Total Body Irradiation and Autologous Peripheral Blood Progenitor Cell Transplantation in Rhesus Macaques. Stem Cells, 2006, 24, 1539-1548.	3.2	7
149	Combination therapy with rFVIIa and platelets for hemorrhage in patients with severe thrombocytopenia and alloimmunization. American Journal of Hematology, 2006, 81, 218-219.	4.1	21
150	GMA161 Treatment of Refractory ITP: Efficacy of FcÎ³-RIII Blockade.. Blood, 2006, 108, 1074-1074.	1.4	5
151	PU.1 Is a Downstream Target of SOX4 in Myeloid Cells.. Blood, 2006, 108, 2217-2217.	1.4	0
152	MDS1-EVI1 and EVI1 Overexpression Results in Changes in the Behavior of Murine Hematopoietic Cells.. Blood, 2006, 108, 1452-1452.	1.4	0
153	Ex Vivo Expansion of Retrovirally-Transduced Primate CD34+ Cells Results in Preferential Engraftment and Persistence of Clones with MDS1/EVI1 Insertion Sites.. Blood, 2006, 108, 203-203.	1.4	0
154	Anti-interleukin-2 receptor antibody (daclizumab) treatment of corticosteroid-refractory autoimmune thrombocytopenic purpura. Haematologica, 2006, 91, 277-8.	3.5	14
155	Large Animal Models for Stem and Progenitor Cell Analysis. Current Protocols in Immunology, 2005, 69, Unit 22A.1.	3.6	34
156	Low-dose total body irradiation causes clonal fluctuation of primate hematopoietic stem and progenitor cells. Blood, 2005, 105, 1010-1015.	1.4	23
157	Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood, 2005, 105, 2473-2479.	1.4	264
158	Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. Blood, 2005, 106, 2530-2533.	1.4	150
159	Stem Cell Gene Transfer: Insights into Integration and Hematopoiesis from Primate Genetic Marking Studies. Annals of the New York Academy of Sciences, 2005, 1044, 178-182.	3.8	18
160	Hematopoietic stem cell gene therapy: dead or alive?. Trends in Biotechnology, 2005, 23, 589-597.	9.3	26
161	Large granular lymphocytic proliferation-associated cyclic thrombocytopenia. American Journal of Hematology, 2005, 79, 334-336.	4.1	26
162	Prediction and prevention of transplant-related mortality from pulmonary causes after total body irradiation and allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation, 2005, 11, 223-230.	2.0	58

#	Article	IF	Citations
163	Outcomes and Risks of Granulocyte Colony-Stimulating Factor in Patients With Coronary Artery Disease. Journal of the American College of Cardiology, 2005, 46, 1643-1648.	2.8	206
164	A new direction for gene therapy: intrathymic T cell-specific lentiviral gene transfer. Journal of Clinical Investigation, 2005, 115, 2064-2067.	8.2	9
165	Hematopoietic Stem Cell Mobilization and Homing. , 2004, , 593-607.		2
166	Imatinib-Responsive Hypereosinophilia in a Patient with B Cell ALL. Leukemia and Lymphoma, 2004, 45, 2497-2501.	1.3	21
167	MRI detection of single particles for cellular imaging. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10901-10906.	7.1	468
168	Long-Term Clinical and Molecular Follow-up of Large Animals Receiving Retrovirally Transduced Stem and Progenitor Cells: No Progression to Clonal Hematopoiesis or Leukemia. Molecular Therapy, 2004, 9, 389-395.	8.2	94
169	Distinct Genomic Integration of MLV and SIV Vectors in Primate Hematopoietic Stem and Progenitor Cells. PLoS Biology, 2004, 2, e423.	5.6	243
170	The presence of the carboxy-terminal fragment of fibronectin allows maintenance of non-human primate long-term hematopoietic repopulating cells during extended ex vivo culture and transduction. Experimental Hematology, 2004, 32, 163-170.	0.4	16
171	In vivo gene marking of rhesus macaque long-term repopulating hematopoietic cells using a VSV-G pseudotyped versus amphotropic oncoretroviral vector. Journal of Gene Medicine, 2004, 6, 367-373.	2.8	13
172	Genetic manipulation of hematopoietic stem cells. Seminars in Hematology, 2004, 41, 257-271.	3.4	25
173	Transient in vivo selection of transduced peripheral blood cells using antifolate drug selection in rhesus macaques that received transplants with hematopoietic stem cells expressing dihydrofolate reductase vectors. Blood, 2004, 103, 796-803.	1.4	46
174	Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood, 2004, 103, 473-478.	1.4	237
175	Effect of chronic cytokine therapy on clonal dynamics in nonhuman primates. Blood, 2004, 103, 4070-4077.	1.4	14
176	The impact of low-dose busulfan on clonal dynamics in nonhuman primates. Blood, 2004, 104, 1273-1280.	1.4	38
177	Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virusâ€“based lentiviral vector system. Blood, 2004, 103, 4062-4069.	1.4	161
178	Lineage Analysis of the FIPL1-PDGFRÎ± Fusion Gene in Myeloproliferative Hypereosinophilic Syndrome.. Blood, 2004, 104, 2441-2441.	1.4	9
179	New Aspects on the Safety of Multidrug-Resistance 1 Gene Transfers: No Indication for Clonal Dominance after Long-Term Follow-Up in a Primate Transplantation Model.. Blood, 2004, 104, 2108-2108.	1.4	0
180	In Vitro Culture during Retroviral Transduction Improves Thymic Repopulation and Output after TBI and Autologous PBPC Transplantation in Rhesus Macaques.. Blood, 2004, 104, 1196-1196.	1.4	0

#	Article	IF	Citations
181	Proliferation of CD8+ T-Cells Specific for CMV and EBV in Response to TCR Mediated Recognition of Cognate Antigen Is Inhibited by Imatinib in a Dose-Dependent Manner.. Blood, 2004, 104, 1342-1342.	1.4	0
182	Serial Cardiac Magnetic Resonance Imaging of Injected Mesenchymal Stem Cells. Circulation, 2003, 108, 1009-1014.	1.6	457
183	T cell receptor VB repertoire diversity in patients with immune thrombocytopenia following splenectomy. Clinical and Experimental Immunology, 2003, 133, 461-466.	2.6	22
184	Efficient Characterization of Retroâ€, Lentiâ€, and Foamyvectorâ€Transduced Cell Populations by Highâ€Accuracy Insertion Site Sequencing. Annals of the New York Academy of Sciences, 2003, 996, 112-121.	3.8	20
185	Prolonged multilineage clonal hematopoiesis in a rhesus recipient of CD34 positive cells marked with a RD114 pseudotyped oncoretroviral vector. Blood Cells, Molecules, and Diseases, 2003, 30, 132-143.	1.4	21
186	High-dose cyclophosphamide with autologous lymphocyteâ€"depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood, 2003, 101, 71-77.	1.4	95
187	American society of gene therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Molecular Therapy, 2003, 8, 180-187.	8.2	147
188	Direct comparison of RD114-pseudotyped versus amphotropic-pseudotyped retroviral vectors for transduction of rhesus macaque long-term repopulating cells. Molecular Therapy, 2003, 8, 611-617.	8.2	18
189	Retroviral transduction efficiency of G-CSF+SCFâ€"mobilized peripheral blood CD34+ cells is superior to G-CSF or G-CSF+Flt3-Lâ€"mobilized cells in nonhuman primates. Blood, 2003, 101, 2199-2205.	1.4	48
190	Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood, 2003, 101, 2563-2569.	1.4	203
191	Highly efficient endosomal labeling of progenitor and stem cells with large magnetic particles allows magnetic resonance imaging of single cells. Blood, 2003, 102, 867-872.	1.4	404
192	Resetting the immune system in immune thrombocytopenic purpura: immunoablative strategies. Clinical Advances in Hematology and Oncology, 2003, 1, 365-71.	0.3	2
193	Retroviral Transduction and Engraftment Ability of Primate Hematopoietic Progenitor and Stem Cells Transduced Under Serum-Free versus Serum-Containing Conditions. Molecular Therapy, 2002, 5, 316-322.	8.2	19
194	Polyclonal long-term repopulating stem cell clones in a primate model. Blood, 2002, 100, 2737-2743.	1.4	219
195	Plasticity and hematopoiesis: Circe's transforming potion?. Current Opinion in Hematology, 2002, 9, 268-273.	2.5	8
196	Lentiviruses get specific. Blood, 2002, 99, 397-397.	1.4	4
197	Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor Î² receptor fusion oncogene. Blood, 2002, 100, 1088-1091.	1.4	117
198	Antithymocyte Globulin for Treatment of the Bone Marrow Failure Associated with Myelodysplastic Syndromes. Annals of Internal Medicine, 2002, 137, 156.	3.9	196

#	Article	IF	Citations
199	Absence of donor-derived keratinocyte stem cells in skin tissues cultured from patients after mobilized peripheral blood hematopoietic stem cell transplantation. Experimental Hematology, 2002, 30, 943-949.	0.4	45
200	Genetic marking as an approach to studying in vivo hematopoiesis: progress in the non-human primate model. Oncogene, 2002, 21, 3274-3283.	5.9	30
201	Update on hematopoietic stem cell gene transfer using non-human primate models. Current Opinion in Molecular Therapeutics, 2002, 4, 482-90.	2.8	12
202	Gene therapy approaches for multiple myeloma. Seminars in Hematology, 2001, 38, 268-275.	3.4	10
203	The effect of multidrug-resistance 1 gene versus neotransduction on ex vivo and in vivo expansion of rhesus macaque hematopoietic repopulating cells. Blood, 2001, 97, 1888-1891.	1.4	58
204	Rabaptin-5 is a novel fusion partner to platelet-derived growth factor Î² receptor in chronic myelomonocytic leukemia. Blood, 2001, 98, 2518-2525.	1.4	134
205	Transplant dose of CD34+ and CD3+ cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back. British Journal of Haematology, 2001, 115, 95-104.	2.5	62
206	Assessment of rapid remobilization intervals with G-CSF and SCF in murine and rhesus macaque models. Transfusion, 2001, 41, 1438-1444.	1.6	11
207	In VivoPersistence of Retrovirally Transduced Murine Long-Term Repopulating Cells Is Not Limited by Expression of Foreign Gene Products in the Fully or Minimally Myeloablated Setting. Human Gene Therapy, 2001, 12, 1663-1672.	2.7	32
208	Update on the Use of Nonhuman Primate Models for Preclinical Testing of Gene Therapy Approaches Targeting Hematopoietic Cells. Human Gene Therapy, 2001, 12, 607-617.	2.7	76
209	The Impact of <i>ex Vivo</i> Cytokine Stimulation on Engraftment of Primitive Hematopoietic Cells in a Nonâ€Human Primate Model. Annals of the New York Academy of Sciences, 2001, 938, 236-245.	3.8	19
210	Avoidance of stimulation improves engraftment of cultured and retrovirally transduced hematopoietic cells in primates. Journal of Clinical Investigation, 2001, 108, 447-455.	8.2	89
211	Many multipotential gene-marked progenitor or stem cell clones contribute to hematopoiesis in nonhuman primates. Blood, 2000, 96, 1-8.	1.4	112
212	Introduction of a Xenogeneic Gene via Hematopoietic Stem Cells Leads to Specific Tolerance in a Rhesus Monkey Model. Molecular Therapy, 2000, 1, 533-544.	8.2	73
213	Prolonged High-Level Detection of Retrovirally Marked Hematopoietic Cells in Nonhuman Primates after Transduction of CD34+ Progenitors Using Clinically Feasible Methods. Molecular Therapy, 2000, 1, 285-293.	8.2	111
214	High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet, The, 2000, 356, 1554-1559.	13.7	151
215	Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation. New England Journal of Medicine, 2000, 343, 750-758.	27.0	977
216	Primary T Lymphocytes as Targets for Gene Therapy. Journal of Hematotherapy and Stem Cell Research, 2000, 9, 611-620.	1.8	14

#	Article	IF	Citations
217	Many multipotential gene-marked progenitor or stem cell clones contribute to hematopoiesis in nonhuman primates. Blood, 2000, 96, 1-8.	1.4	3
218	Basic Studies Toward Hematopoietic Stem Cell Gene Therapy. , 2000, , 159-169.		0
219	Engraftment of MDR1 and NeoR Gene-Transduced Hematopoietic Cells After Breast Cancer Chemotherapy. Blood, 1999, 94, 52-61.	1.4	142
220	In Vivo Marking of Rhesus Monkey Lymphocytes by Adeno-Associated Viral Vectors: Direct Comparison With Retroviral Vectors. Blood, 1999, 94, 2263-2270.	1.4	41
221	Expression of interferon-Î³ by stromal cells inhibits murine long-term repopulating hematopoietic stem cell activity. Experimental Hematology, 1999, 27, 895-903.	0.4	23
222	No Discrepancy between in Vivo Gene Marking Efficiency Assessed in Peripheral Blood Populations Compared with Bone Marrow Progenitors or CD34+ Cells. Human Gene Therapy, 1999, 10, 633-640.	2.7	18
223	CNS Interleukin-3 (IL-3) Expression and Neurological Syndrome in Antisense-IL-3 Transgenic Mice. Journal of Neuropathology and Experimental Neurology, 1999, 58, 480-488.	1.7	15
224	Improved Amphotropic Retrovirus-Mediated Gene Transfer into Hematopoietic Stem Cells. Annals of the New York Academy of Sciences, 1998, 850, 139-150.	3.8	20
225	Murine Bone Marrow Expressing the Neomycin Resistance Gene Has No Competitive Disadvantage Assessed<i>In Vivo</i>. Human Gene Therapy, 1998, 9, 1157-1164.	2.7	16
226	Retroviral Transfer of the Glucocerebrosidase Gene into CD34⁺Cells from Patients with Gaucher Disease:<i>In Vivo</i>Detection of Transduced Cells without Myeloablation. Human Gene Therapy, 1998, 9, 2629-2640.	2.7	144
227	Retroviral Transfer of the Glucocerebrosidase Gene into CD34+ Cells from Patients with Gaucher Disease: In Vivo Detection of Transduced Cells without Myeloablation. Human Gene Therapy, 1998, 9, 2629-2640.	2.7	112
228	Gene Transfer to Hematopoietic Cells: Progress and Problems. Leukemia and Lymphoma, 1998, 30, 15-16.	1.3	0
229	Green Fluorescent Protein Retroviral Vectors: Low Titer and High Recombination Frequency Suggest a Selective Disadvantage. Human Gene Therapy, 1997, 8, 1313-1319.	2.7	95
230	Retroviral Mediated Gene Transfer of the Fanconi Anemia Complementation Group C Gene to Hematopoietic Progenitors of Group C Patients. National Institutes of Health, Bethesda, Maryland. Human Gene Therapy, 1997, 8, 1715-1730.	2.7	38
231	Hepatitis-Associated Aplastic Anemia. New England Journal of Medicine, 1997, 336, 1059-1064.	27.0	293
232	Murine Long-Term Repopulating Ability Is Compromised by Ex Vivo Culture in Serum-Free Medium Despite Preservation of Committed Progenitors. Stem Cells and Development, 1997, 6, 543-549.	1.0	19
233	Transduction of hematopoietic stem cells in humans and in nonhuman primates. Stem Cells, 1997, 15, 135-140.	3.2	28
234	Gene marking and gene therapy directed at primary hematopoietic cells. Current Opinion in Hematology, 1996, 3, 430-437.	2.5	46

#	Article	IF	Citations
235	Retroviral Mediated Transfer of the cDNA for Human Glucocerebrosidase into Hematopoietic Stem Cells of Patients with Gaucher Disease. A Phase I Study. National Institutes of Health, Bethesda, Maryland. Human Gene Therapy, 1996, 7, 231-253.	2.7	54
236	Retroviral Transduction of CD34-Enriched Hematopoietic Progenitor Cells Under Serum-Free Conditions. Human Gene Therapy, 1996, 7, 33-38.	2.7	21
237	GENE TRANSFER TO HEMATOPOIETIC STEM CELLS: Implications for Gene Therapy of Human Disease. Annual Review of Medicine, 1996, 47, 11-20.	12.2	72
238	Retroviral Mediated Transfer of the Human Multidrug Resistance Gene (MDR-1) into Hematopoietic Stem Cells During Autologous Transplantation after Intensive Chemotherapy for Metastatic Breast Cancer. National Institutes of Health, Bethesda, Maryland. Human Gene Therapy, 1994, 5, 891-911.	2.7	84
239	Gene transfer into hematopoietic progenitor and stem cells: Progress and problems. Stem Cells, 1994, 12, 563-576.	3.2	81
240	Gene Transfer into Hematopoietic Cells: Implications for Cancer Therapy. Annals of the New York Academy of Sciences, 1994, 716, 216-224.	3.8	25
241	Amendment to Clinical Research Projects: Genetic Marking With Retroviral Vectors to Study the Feasibility of Stem Cell Gene Transfer and the Biology of Hematopoietic Reconstitution After Autologous Transplantation in Multiple Myeloma, Chronic Myelogenous Leukemia, or Metastatic Breast Cancer. Human Gene Therapy, 1993, 4, 205-222.	2.7	30
242	Pilot Study of High Dose ICE (Ifosfamide, Carboplatin, Etoposide) Chemotherapy and Autologous Bone Marrow Transplant (ABMT) withneoR-Transduced Bone Marrow and Peripheral Blood Stem Cells in Patients with Metastatic Breast Cancer. National Cancer Institute. Human Gene Therapy, 1993, 4, 331-354.	2.7	13
243	Treatment of Diamond-Blackfan anaemia with haematopoietic growth factors, granulocyte-macrophage colony stimulating factor and interleukin 3: sustained remissions following IL-3. British Journal of Haematology, 1991, 79, 316-321.	2.5	51
244	5-AZACYTIDINE TREATMENT IN A Î²0-THALASSAEMIC PATIENT UNABLE TO BE TRANSFUSED DUE TO MULTIPLE ALLOANTIBODIES. British Journal of Haematology, 1989, 72, 467-467.	2.5	27
245	Gene Therapy for Hematological Disorders. , 0, , 133-152.		1